The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (S-1+Oxaliplatin) and radiotherapy for locally advanced esophagogastric junction adenocarcinoma.
Wuhan, Hubei 430030, China
Age 18-70, male and female.
Histologically confirmed locally advanced esophagogastric junction Adenocarcinoma cT3-4aNxM0 (AJCC v8), Siewert typed as type II-III.
No previous anti-tumor treatment.
ECOG score was 0-1.
Expected survival of ≥ 6 months
Adequate organ reserve function.
Malignant disease other than gastric cancer (excluding radically treated basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and/or radically resected carcinoma in situ) diagnosed within 5 years.
Known Her-2 positive( IHC 3+ or FISH positve).
Patients have received immunotherapy, such as PD-1 antibody, PD-L1 antibody and CTLA4 antibody
Severe allergic reaction to monoclonal antibody.
Receiving systemic glucocorticoid therapy within 7 days prior to the first dose of the study
Known endoscopic signs of active bleeding from the lesion
Study Contact Info
Contact Listings Owner Form
Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction 0 reviewsWrite Your Review
There are no reviews yet.